can dpp4 and glp 1 be given together Clinical Use of DPP-4 Inhibitors do not combine dpp-4 inhibitors

With 1 in 10 adults suffering from type 2 diabetes and 4 in 10 categorized as overweight or obese, the combined market for these conditions currently stands at $100B and is projected to exceed $250B within the next decade

For people with diabetes, the sustained HbA1c improvements that tirzepatide produces over years of use represent ongoing protection against the UTI risk that poorly controlled blood sugar creates

rskov, C., Poulsen, S

Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight

Medicare historically did not cover weight-loss-only indications, but the 2026 GLP-1 Bridge program allows Medicare patients $50/month access to Foundayo through December 2026